Brief: Zymeworks Presents New Phase 1 Data For Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191
Today 07:41
BRIEF-Zymeworks Presents New Phase 1 Data For Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 Oct 24 (Reuters) - Zymeworks Inc. ZYME.O:
ZYMEWORKS PRESENTS NEW PHASE 1 DATA FOR FOLATE RECEPTOR ALPHA-TARGETING ANTIBODY-DRUG CONJUGATE ZW191 AT ESMO CONGRESS 2026
ZYMEWORKS - ZW191 DEMONSTRATES ANTI-TUMOR ACTIVITY IN PLATINUM-RESISTANT OVARIAN CANCER ACROSS FRΑ EXPRESSION LEVELS
ZYMEWORKS - ZW191 ACHIEVES CORR OF 64.5% AT 6.4 MG/KG IN HIGH-GRADE SEROUS PROC
ZYMEWORKS - MEDIAN DURATION OF RESPONSE NOT REACHED; SIX-MONTH PFS RATE OF 61% IN BOTH GROUPS
Source text: ID:nGNX40y3HD
Further company coverage: ZYME.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zymeworks
See all newsBrief: Zymeworks Presents New Phase 1 Data For Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191
US STOCKS ON THE MOVE-Huron Consulting, RingCentral, Selective Insurance
U.S. STOCKS ON THE MOVE-Huron Consulting, Crown Castle, Bloom Energy
US STOCKS ON THE MOVE-Booz Allen Hamilton, SLB, Deckers Outdoor
US STOCKS ON THE MOVE-American Express, Gorman-Rupp, Moderna